Adherence to Guidelines for Screening and Medication Use: Mortality and Onset of Major Macrovascular Complications in Elderly Persons With Diabetes Mellitus

Abstract

Elderly persons newly diagnosed with diabetes who adhered to recommended care experienced reduced risk of mortality and severe macrovascular complications.

The association between medication non‐adherence and adverse health outcomes in ageing populations: A systematic review and meta‐analysis

“…The included studies focussed on a wide range of disease areas including pulmonary diseases, osteoporosis, depression, cardiovascular diseases, Parkinson's disease, epilepsy, chronic kidney disease, cancer and diabetes mellitus . Two studies did not measure disease‐specific medication (non‐)adherence .…”

“…Two studies did not measure disease‐specific medication (non‐)adherence . Thirty‐six studies were specific to, or provided age stratified analysis for people aged ≥64 years, while the other 30 studies also included middle aged adults (≥50 years) . Thirteen authors of the included texts were contacted via e‐mail for further information, and 8 replied.…”

“…Thirteen authors of the included texts were contacted via e‐mail for further information, and 8 replied. In terms of adherence measurement, 54 studies measured medication (non‐)adherence using pharmacy claims data while 11 studies used self‐report methods, consisting of the 4‐item or 8‐item Morisky Medication Adherence Scale, or self‐reported PDC and MEMs was used in 4 studies …”

“…Overall, 48 studies were determined to be high quality, 17 were determined to be medium quality and 1 study was deemed to be low quality (Table S8). There was considerable variability with regards to external validity (generalisability), with 15 studies deemed medium quality and 11 studies achieving low quality . This was due to lack of detail on sampling or recruitment procedures or inclusion of specific populations only.…”

“…Exposure period was the same as the outcome measurement period in 9 studies measuring healthcare utilisation or adverse clinical outcomes (not censored at first incidence of event) . Most included studies utilised large pharmacoepidemiological administrative data sources allowing for sufficiently powered analyses I Healthcare utilisation …”